| Gemcitabine: current status of phase I and II trials |
| SB Kaye |
|
JCO Aug 1 1994: 1527–1531.
[PDF]
|
 |
| Attainment of molecular remission: a worthwhile goal? |
| JG Gribben |
|
JCO Aug 1 1994: 1532–1534.
[PDF]
|
|
|
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study |
| |
RP Abratt, WR Bezwoda, G Falkson, L Goedhals, D Hacking, and TA Rugg |
| |
JCO Aug 1 1994: 1535–1540.
[Abstract]
[PDF]
|
|
|
Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission |
| |
AC Lambrechts, PE Hupkes, LC Dorssers, and MB van't Veer |
| |
JCO Aug 1 1994: 1541–1546.
[Abstract]
[PDF]
|
|
|
Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer |
| |
K Kubota, K Furuse, M Kawahara, N Kodama, M Yamamoto, M Ogawara, S Negoro, N Masuda, M Takada, and K Matsui |
| |
JCO Aug 1 1994: 1547–1552.
[Abstract]
[PDF]
|
|
|
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma |
| |
MB Atkins, KR O'Boyle, JA Sosman, GR Weiss, KA Margolin, ML Ernest, K Kappler, JW Mier, JA Sparano, and RI Fisher |
| |
JCO Aug 1 1994: 1553–1560.
[Abstract]
[PDF]
|
|
|
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer |
| |
S Welt, CR Divgi, N Kemeny, RD Finn, AM Scott, M Graham, JS Germain, EC Richards, SM Larson, and HF Oettgen |
| |
JCO Aug 1 1994: 1561–1571.
[Abstract]
[PDF]
|
|
|
Randomized comparison of high-dose and low-dose intravenous interleukin- 2 for the therapy of metastatic renal cell carcinoma: an interim report |
| |
JC Yang, SL Topalian, D Parkinson, DJ Schwartzentruber, JS Weber, SE Ettinghausen, DE White, SM Steinberg, DJ Cole, and HI Kim |
| |
JCO Aug 1 1994: 1572–1576.
[Abstract]
[PDF]
|
|
|
Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945 |
| |
RA Kyle, CM Beard, WM O'Fallon, and LT Kurland |
| |
JCO Aug 1 1994: 1577–1583.
[Abstract]
[PDF]
|
|
|
Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells |
| |
P Sonneveld, M Schoester, and K de Leeuw |
| |
JCO Aug 1 1994: 1584–1591.
[Abstract]
[PDF]
|
|
|
Tumor response, toxicity, and survival after neoadjuvant organ- preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group |
| |
MB Spaulding, SG Fischer, and GT Wolf |
| |
JCO Aug 1 1994: 1592–1599.
[Abstract]
[PDF]
|
|
|
Correlation of DNA content of laryngeal epithelial lesions to degree of malignancy |
| |
A Ispizua, A Baroja, and C de la Hoz |
| |
JCO Aug 1 1994: 1600–1606.
[Abstract]
[PDF]
|
|
|
Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group |
| |
JR Geyer, PM Zeltzer, JM Boyett, LB Rorke, P Stanley, AL Albright, JH Wisoff, JM Milstein, JC Allen, and JL Finlay |
| |
JCO Aug 1 1994: 1607–1615.
[Abstract]
[PDF]
|
|
|
Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study |
| |
RP Castleberry, AB Cantor, AA Green, V Joshi, RL Berkow, GR Buchanan, B Leventhal, DH Mahoney, EI Smith, and FA Hayes |
| |
JCO Aug 1 1994: 1616–1620.
[Abstract]
[PDF]
|
|
|
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion |
| |
WH Wilson, SL Berg, G Bryant, RE Wittes, S Bates, A Fojo, SM Steinberg, BR Goldspiel, J Herdt, and J O'Shaughnessy |
| |
JCO Aug 1 1994: 1621–1629.
[Abstract]
[PDF]
|
|
|
Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study |
| |
HB Muss, LD Case, JN Atkins, JD Bearden, 3rd, MR Cooper, JM Cruz, DV Jackson, Jr, MA O'Rourke, MD Pavy, and BL Powell |
| |
JCO Aug 1 1994: 1630–1638.
[Abstract]
[PDF]
|
|
|
Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer |
| |
K Porkka, C Blomqvist, P Rissanen, I Elomaa, and S Pyrhonen |
| |
JCO Aug 1 1994: 1639–1647.
[Abstract]
[PDF]
|
|
|
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer |
| |
JA Foekens, M Schmitt, WL van Putten, HA Peters, MD Kramer, F Janicke, and JG Klijn |
| |
JCO Aug 1 1994: 1648–1658.
[Abstract]
[PDF]
|
|
|
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy |
| |
RL Basser, MM Sobol, G Duggan, J Cebon, MA Rosenthal, G Mihaly, and MD Green |
| |
JCO Aug 1 1994: 1659–1666.
[Abstract]
[PDF]
|
|
|
Patient characteristics associated with high-risk methotrexate concentrations and toxicity |
| |
MV Relling, D Fairclough, D Ayers, WR Crom, JH Rodman, CH Pui, and WE Evans |
| |
JCO Aug 1 1994: 1667–1672.
[Abstract]
[PDF]
|
|
|
Non-Hodgkin's lymphoma of the gastrointestinal tract: a population- based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group |
| |
F d'Amore, H Brincker, K Gronbaek, K Thorling, M Pedersen, MK Jensen, E Andersen, NT Pedersen, and LS Mortensen |
| |
JCO Aug 1 1994: 1673–1684.
[Abstract]
[PDF]
|
|
|
Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma |
| |
R Haas, M Moos, A Karcher, R Mohle, B Witt, H Goldschmidt, S Fruhauf, M Flentje, M Wannenmacher, and W Hunstein |
| |
JCO Aug 1 1994: 1685–1692.
[Abstract]
[PDF]
|
|
|
Development of a simplified single-apheresis approach for peripheral- blood progenitor-cell transplantation in previously treated patients with lymphoma |
| |
HM Jones, SA Jones, MJ Watts, A Khwaja, W Mills, A Fielding, AH Goldstone, and DC Linch |
| |
JCO Aug 1 1994: 1693–1702.
[Abstract]
[PDF]
|
|
|
Transient acantholytic dermatosis in oncology patients |
| |
AL Guana and PR Cohen |
| |
JCO Aug 1 1994: 1703–1709.
[Abstract]
[PDF]
|
|
|
Leukemia: management of relapse after allogeneic bone marrow transplantation |
| |
L Kumar |
| |
JCO Aug 1 1994: 1710–1717.
[Abstract]
[PDF]
|
|
|
The Community Clinical Oncology Program (CCOP) story: review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987 |
| |
RW Frelick |
| |
JCO Aug 1 1994: 1718–1723.
[Abstract]
[PDF]
|
|
|
Quantitating familial cancer risk: a resource for clinical oncologists |
| |
K Offit and K Brown |
| |
JCO Aug 1 1994: 1724–1736.
[Abstract]
[PDF]
|
|
| Bone marrow transplant in acute myeloid leukemia |
| D Pinkel |
|
JCO Aug 1 1994: 1737a.
[PDF]
|
|
| Prognostic factors for women with ovarian germ cell tumors |
| JI Mayordomo, L Paz-Ares, MT Diaz-Puente, P Lianes, MD Garcia-Prats, and H Cortes- Funes |
|
JCO Aug 1 1994: 1737b–1738.
[PDF]
|
|
| Clarification of entry criteria for the European Organization for Research and Treatment of Cancer H5-favorable trial of early-stage Hodgkin's disease |
| GM Rasp, MG Haddock, and JA Martenson |
|
JCO Aug 1 1994: 1739–1740.
[PDF]
|
|
| Calvert's formula and high-dose carboplatin |
| B Uziely, SC Formenti, K Watkins, A Mazumder, and FM Muggia |
|
JCO Aug 1 1994: 1740–1741.
[PDF]
|
|
| Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2 |
| AD Seidman, S Barrett, and S Canezo |
|
JCO Aug 1 1994: 1741–1742.
[PDF]
|
|
